While SLE, SS, and alopecia exhibit reduced VEGFR3 signaling, RA, UC, CD, and IBD display increased VEGFR3 signaling; thus, both pro- and anti-lymphatic therapies are in play, depending on the disease type. This evidence concerns the gene FLT4 and systemic lupus erythematosus.